Here we are Now, Enable us | Predictions for 2025
Michael Poku, M.D., chief clinical officer of Equality Health, shared his prediction for 2025.
Payers are increasingly recognizing the transformative potential of value-based care enablers. In 2025, payers will actively collaborate with these specialized organizations like never before to strengthen connections with providers, particularly independent primary care practices, and streamline activities critical to value-based care success. This will involve a strong focus on promoting member-centered care and services.
Poku
Expect to see more value-based care enablers entering the market, each offering innovative models designed to support providers in diverse ways. These models will range from reducing administrative burdens and standardizing payer relationships to simplifying quality metric reporting and leveraging technologies for proactive clinical workflows and preventive care.
Such partnerships will offload and downstream enablement from payer organizations, which will be essential for scaling value-based care, moving away from fee-for-service and achieving measurable improvements in health outcomes and cost reduction.
Medicaid Cuts Remain Center Stage as Experts Address Industry Challenges
March 28th 2025In a recent conversation with Jennifer McGuigan Babcock, senior vice president for Medicaid policy at the Association for Community Affiliated Plans (ACAP), and Gabe Scott, a partner at K&L Gates Health Care Group, the two discussed efforts to protect Medicaid’s role in the healthcare system and the consequences of the budget cuts announced in February.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
